M Franken
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Economics and Econometrics top 5%
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Economic and Financial Impacts of Cancer
Papers in
-
- Health Systems, Economic Evaluations, Quality of Life 21
- Pharmaceutical Economics and Policy 9
- Economic and Financial Impacts of Cancer 4
- Oncology 12
- Cutaneous Melanoma Detection and Management 7
- Cancer Treatment and Pharmacology 3
- CAR-T cell therapy research 3
- Co-authors
- Carin A. Uyl‐de Groot (21 shared papers)Marc Koopmanschap (9 shared papers)Hedwig M. Blommestein (13 shared papers)Pieter Sonneveld (9 shared papers)Irina Cleemput (4 shared papers)B Leeneman (10 shared papers)Xander Koolman (1 shared paper)Anthonius de Boer (2 shared papers)
- Journals
- Value in Health (16 papers)Health Policy (4 papers)European Journal of Cancer (4 papers)International Journal of Technology Assessment in Health Care (4 papers)PharmacoEconomics (2 papers)
- Partner nations
- NetherlandsUnited StatesBelgium
In The Last Decade
M Franken
50 papers receiving 670 citations
Peers
Comparison fields: 5 of 93
- Hematology 149
- Economics and Econometrics 199
- Oncology 150
- Management of Technology and Innovation 22
- Genetics 23
Countries citing papers authored by M Franken
This map shows the geographic impact of M Franken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Franken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Franken more than expected).
Fields of papers citing papers by M Franken
This network shows the impact of papers produced by M Franken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Franken. The network helps show where M Franken may publish in the future.
Co-authors
The 25 scholars most cited alongside M Franken, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 90 | |
| 2 | 2012 | 60 | |
| 3 | 2012 | 41 | |
| 4 | 2016 | 33 | |
| 5 | 2019 | 31 | |
| 6 | 2018 | 30 | |
| 7 | 2021 | 28 | |
| 8 | 2014 | 28 | |
| 9 | 2013 | 28 | |
| 10 | 2010 | 28 | |
| 11 | 2013 | 27 | |
| 12 | 2015 | 26 | |
| 13 | 2019 | 25 | |
| 14 | 2012 | 23 | |
| 15 | 2021 | 22 | |
| 16 | 2019 | 21 | |
| 17 | 2020 | 19 | |
| 18 | 2014 | 17 | |
| 19 | 2020 | 12 | |
| 20 | 2016 | 10 |
About M Franken
M Franken is a scholar working on Economics and Econometrics, Oncology, Hematology, Molecular Biology and General Health Professions, having authored 52 papers that have together received 702 indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (21 papers), Pharmaceutical Economics and Policy (9 papers), Multiple Myeloma Research and Treatments (9 papers), Cutaneous Melanoma Detection and Management (7 papers), Economic and Financial Impacts of Cancer (4 papers), Protein Degradation and Inhibitors (3 papers), Cancer Treatment and Pharmacology (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Hematology (149 citations), Economics and Econometrics (199 citations), Oncology (150 citations), Management of Technology and Innovation (22 citations) and Genetics (23 citations). M Franken has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Carin A. Uyl‐de Groot, Marc Koopmanschap, Hedwig M. Blommestein, Pieter Sonneveld, Irina Cleemput, B Leeneman, Xander Koolman, Anthonius de Boer, Peter C. Huijgens and John B.A.G. Haanen. Their work appears in journals such as Value in Health, Health Policy, European Journal of Cancer, International Journal of Technology Assessment in Health Care and PharmacoEconomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.